David versus Goliath: Radiotheranostic nanomedicine as a weapon against melanoma
Luca Filippi1, Viviana Frantellizzi2, Giuseppe De Vincentis2
1Department of Nuclear Medicine, "Santa Maria Goretti" Hospital, via Canova, Latina, 04100, Italy.
Abstract:
Malignant melanoma (MM), especially when diagnosed at an advanced stage, still represents a challenge for physicians. In recent years, immune check point inhibitors (ICI) have thoroughly changed MM landscape, although only 20-40% of MM patients respond to ICI. In MM progressing after ICI, treatment options, especially in case of MM not bearing V600 mutation, are limited. In this scenario, radionuclide theranostics, based on the sequential administration of a radiopharmaceuticals' pair, the first labeled with a radionuclide emitting energy suitable for imaging (i.e. positrons or gamma-rays), the second bound to another nuclide emitting particles for therapy, is particularly welcome. Melanocortin 1 Receptor (MC1R), strongly overexpressed by MM cells, has recently emerged as an interesting target for radionuclide theranostics. In the following, we briefly cover some emerging applications of MC1R-targeted radionuclide theranostics, also with reference to the potential of implementing some innovative nanotechnologies, such as gold nanoparticles, to move the field forward.
Insights
Advanced melanoma remains challenging, especially after immune checkpoint inhibitor (ICI) therapy. Melanocortin 1 Receptor (MC1R)-targeted radionuclide theranostics offer a promising new approach for treating malignant melanoma (MM) patients.
Area of Science:
- Oncology
- Nuclear Medicine
- Nanotechnology
Background:
- Malignant melanoma (MM) presents significant treatment challenges, particularly in advanced stages and following immune checkpoint inhibitor (ICI) therapy.
- Current treatment options for ICI-resistant or V600-unmutated MM are limited.
- Immune checkpoint inhibitors (ICI) have improved outcomes but benefit only 20-40% of patients.
Purpose of the Study:
- To explore emerging applications of Melanocortin 1 Receptor (MC1R)-targeted radionuclide theranostics for malignant melanoma (MM).
- To highlight the potential of integrating nanotechnologies, like gold nanoparticles, into MC1R-targeted theranostics.
- To address the unmet need for effective therapies in advanced and ICI-resistant MM.
Main Methods:
- Review of current literature on MC1R-targeted radionuclide theranostics in MM.
- Discussion of the principles of radionuclide theranostics using radiopharmaceutical pairs for imaging and therapy.
- Exploration of nanomedicine applications, specifically gold nanoparticles, for enhanced theranostic delivery.
Main Results:
- Melanocortin 1 Receptor (MC1R) is significantly overexpressed on MM cells, making it a viable therapeutic target.
- Radionuclide theranostics offer a dual approach for imaging and targeted therapy.
- Nanotechnology integration may improve the efficacy and delivery of MC1R-targeted agents.
Conclusions:
- MC1R-targeted radionuclide theranostics represent a promising frontier in MM treatment, especially for refractory cases.
- The combination of MC1R targeting with advanced nanotechnologies holds potential for improved therapeutic outcomes.
- Further research into MC1R-based theranostics and nanomedicine integration is warranted for advanced MM management.
